title: Late loss in a disappearing frame of reference: is it still applicable to fully absorbable scaffolds?
abstract: Bioabsorbable stents are an important advancement in stent technology providing a temporary scaffold and may be augmented with drugs to suppress neointimal hyperplasia.Though changes are being made to the design of the stents, to ensure similar rates of acute recoil, residual stenosis postintervention remains higher when compared to contemporary durable stents. In order to achieve similar clinical restenosis outcomes, bioabsorbable stents must first show similar MLD or percent diameter stenosis at follow-up to drug-eluting stents.While variable different acute gain and post-procedure MLD for bioabsorbable stents make late lumen loss a poor marker for restenosis probability by itself, late loss can be an informative metric for neointimal hyperplasia over time in these stents.Metrics which are independent of acute gain such as minimal luminal diameter and percentage diameter stenosis may make better surrogates for restenosis (Table 1). Moreover, remodelling over time requires measurement of the vessel and lumen diameters in later follow-up. Since the natural history of the vascular response to bioabsorbable stents is in its infancy of investigation, follow-up of these stents at least beyond the duration of polymer is prudent. Finally, given a disappearing frame of reference, both careful angiographic and intravascular ultrasound assessments are helpful to delineate the varying contributions of recoil, remodelling, and neointima formation.
authors.affiliation: Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Clinical Research Institution, Boston, MA 02115, USA.
authors.forename: Sripal
authors.initials: S
authors.lastname: Bangalore
authors.forename: Laura
authors.initials: L
authors.lastname: Mauri
mesh_terms: D020341:Absorbable Implants; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D000818:Animals; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D006801:Humans; D011474:Prosthesis Design; D015607:Stents; D013997:Time Factors; D054457:Tissue Scaffolds; D016896:Treatment Outcome